Ozmosi | Ondansetron Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Ondansetron

Alternative Names: ondansetron, zofran, eur-1025, eur1025, eur 1025, rhb-102, rhb102, rhb 102, BEKINDA, DAS-001, AD04, AD-04, zofran odt, zuplenz
Clinical Status: Inactive
Latest Update: 2026-03-09
Latest Update Note: Clinical Trial Update

Product Description

Ondansetron is one of the medications most commonly used for empiric treatment of nausea and vomiting. Ondansetron has extreme utility as an antiemetic drug, and it is effective against nausea and vomiting of various etiologies.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/29763014/)

Mechanisms of Action: 5-HT3 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous, Oral

FDA Designation: *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: GSK
Company Location: Europe
Company Founding Year: 2000
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ondansetron

Countries in Clinic: Austria, Belgium, China, France, Italy, Poland, Spain, United States

Active Clinical Trial Count: 4

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Acute Pain|Morphine Dependence|Pain, Postoperative

Phase 2: Alzheimer Disease|Fallopian Tube Cancer|Other|Ovarian Cancer|Peritoneal Cancer

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

2022-502983-19-00

ZN‑c3-005

P2

Recruiting

Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cancer

2027-09-01

2025-05-02

Treatments

2024-518523-30-00

ADVANCE-AD04-001

P2

Recruiting

Alzheimer Disease

2026-12-31

2025-05-02

Treatments

NCT04606264

STUDY19030022

P3

Completed

Morphine Dependence|Pain, Postoperative|Acute Pain

2025-03-21

2025-10-23

CTR20170613

CTR20170613

P2

Recruiting

Other

None

2025-04-29

Patient Enrollment|Treatments|Trial Status